EZH2 as an Epigenetic Regulator of Cardiovascular Development and Diseases

Jia-Li Yuan,Cheng-Ye Yin,Ying-Ze Li,Shuai Song,Guo-Jian Fang,Qun-Shan Wang
DOI: https://doi.org/10.1097/FJC.0000000000001062
IF: 3.271
2021-01-01
Journal of Cardiovascular Pharmacology
Abstract:Enhancer of zeste homolog 2(EZH2) is an enzymatic subunit of polycomb repressive complex 2 (PRC2) and is responsible for catalyzing mono-, di-, and trimethylation of histone H3 at lysine-27(H3K27me1/2/3). Many noncoding RNAs or signaling pathways are involved in EZH2 functional alterations. This new epigenetic regulation of target genes is able to silence downstream gene expression and modify physiological and pathological processes in heart development, cardiomyocyte regeneration, and cardiovascular diseases, such as hypertrophy, ischemic heart diseases, atherosclerosis, and cardiac fibrosis. Targeting the function of EZH2 could be a potential therapeutic approach for cardiovascular diseases.
What problem does this paper attempt to address?